Seattle Genetics (SGEN) Announces Initiation of Rituxan Combo Phase 2 as DLBCL Treatment
Tweet Send to a Friend
Seattle Genetics (Nasdaq: SGEN) announced the initiation of a randomized phase 2 clinical trial of Rituxan (rituximab) and bendamustine with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
